Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
galantamine + memantine (Ordain Health Care)
- Development stage
- Unknown
- Lead developer
- Ordain Health Care Global
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Galto Plus is a fixed-dose combination pharmaceutical product containing **galantamine** and **memantine**, developed and marketed by Ordain Health Care (a division of Exeltis) primarily in the Indian market. It is indicated for the treatment of moderate to severe dementia of the Alzheimer's type. Galantamine is a phenanthridine alkaloid that acts as a reversible, competitive inhibitor of acetylcholinesterase and a positive allosteric modulator of nicotinic acetylcholine receptors, thereby enhancing cholinergic neurotransmission. Memantine is a low-to-moderate affinity, non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist that regulates glutamate activity to prevent excitotoxicity. By targeting two distinct neurotransmitter pathways associated with cognitive decline, Galto Plus aims to provide synergistic benefits in managing the symptoms of Alzheimer's disease.
- Brand names
- Galto Plus
- Other names
- Galto Plusgalantamine/memantine
02
Targets
CHRNA7 (α7 nicotinic receptor)α4β2 nAChR (Nicotinic acetylcholine receptor alpha4 beta2 subtype)NMDAR (Glutamate receptor ionotropic, NMDA)Acetylcholinesterase
Beyond the preview
Go deeper on galantamine + memantine (Ordain Health Care).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on galantamine + memantine (Ordain Health Care).